No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Regina Nethery to Retire as Vice President of Investor Relations

Editor: What To Know

  • “Regina's recent recognition as one of the best Investor Relations professionals in Institutional Investor's survey of Wall Street analysts is a testament to her exceptional contributions to the Company.
  • “We are extremely grateful to Regina for her thoughtful, strategic counsel and tremendous contributions to the organization throughout her tenure,” said Dan Cancelmi, Executive Vice President and Chief Financial Officer.
  • “I echo Dan's comments and have found Regina's dedication, resilience and her balance in furthering our transparency to the market to be exceptional,” said Ron Rittenmeyer, Executive Chairman.

Tenet Healthcare Corporation (NYSE: THC) announced today that Regina Nethery, Vice President of Investor Relations, has chosen to retire from her position, effective at the end of 2021.

“We are extremely grateful to Regina for her thoughtful, strategic counsel and tremendous contributions to the organization throughout her tenure,” said Dan Cancelmi, Executive Vice President and Chief Financial Officer. “Regina’s recent recognition as one of the best Investor Relations professionals in Institutional Investor’s survey of Wall Street analysts is a testament to her exceptional contributions to the Company. We will miss Regina and wish her the best on her retirement.”

“I am pleased to have had the opportunity to share Tenet’s corporate strategy and its operational and financial progress with investors,” said Nethery. “I look forward to seeing Tenet’s further growth as I enter this next chapter of my life.”

“I echo Dan’s comments and have found Regina’s dedication, resilience and her balance in furthering our transparency to the market to be exceptional,” said Ron Rittenmeyer, Executive Chairman. “We wish her the very best in retirement.”

Tenet is working with Russell Reynolds Associates to conduct a national search for Nethery’s replacement.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy